Literature DB >> 25268296

Endogenous galactose formation in galactose-1-phosphate uridyltransferase deficiency.

Peter Schadewaldt1, Loganathan Kamalanathan, Hans-Werner Hammen, Jorg Kotzka, Udo Wendel.   

Abstract

Patients with classical galactosaemia (galactose-1-phosphate uridyltransferase (GALT) deficiency) manifest clinical complications despite strict dietary galactose restriction. Therefore the significance of endogenous galactose production has been assessed. Previous in vivo studies primarily focused on patients homozygous for the most common genetic variant Q188R but little is known about other genetic variants. In the present study the endogenous galactose release in a group of non-Q188R homozygous galactosaemic patients (n = 17; 4-34 years) exhibiting comparably low residual GALT activity in red blood cells was investigated. Primed continuous infusion studies with D-[1-(13)C]galactose as substrate were conducted under post-absorptive conditions and in good metabolic control. The results demonstrate that all patients exhibiting residual GALT activity of <1.5% of control showed a comparable pathological pattern of increased endogenous galactose release irrespective of the underlying genetic variations. Possible implications of the findings towards a more differentiated dietary regimen in galactosaemia are discussed.

Entities:  

Keywords:  Carbon isotopes; galactitol; galactonic acid; galactosaemia; galactose; galactose-1-phosphate uridyltransferase; human; metabolism

Mesh:

Substances:

Year:  2014        PMID: 25268296     DOI: 10.3109/13813455.2014.962547

Source DB:  PubMed          Journal:  Arch Physiol Biochem        ISSN: 1381-3455            Impact factor:   4.076


  8 in total

1.  Rigor of non-dairy galactose restriction in early childhood, measured by retrospective survey, does not associate with severity of five long-term outcomes quantified in 231 children and adults with classic galactosemia.

Authors:  Allison B Frederick; David J Cutler; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2017-07-10       Impact factor: 4.982

Review 2.  Inherited Metabolic Disorders: Aspects of Chronic Nutrition Management.

Authors:  Suzanne W Boyer; Lisa J Barclay; Lindsay C Burrage
Journal:  Nutr Clin Pract       Date:  2015-06-16       Impact factor: 3.080

3.  Classical Galactosaemia and CDG, the N-Glycosylation Interface. A Review.

Authors:  Ashwini Maratha; Hugh-Owen Colhoun; Ina Knerr; Karen P Coss; Peter Doran; Eileen P Treacy
Journal:  JIMD Rep       Date:  2016-08-09

Review 4.  Sweet and sour: an update on classic galactosemia.

Authors:  Ana I Coelho; M Estela Rubio-Gozalbo; João B Vicente; Isabel Rivera
Journal:  J Inherit Metab Dis       Date:  2017-03-09       Impact factor: 4.982

5.  A galactose-1-phosphate uridylyltransferase-null rat model of classic galactosemia mimics relevant patient outcomes and reveals tissue-specific and longitudinal differences in galactose metabolism.

Authors:  Shauna A Rasmussen; Jennifer M I Daenzer; Jessica A MacWilliams; S Taylor Head; Martine B Williams; Aron M Geurts; Jason P Schroeder; David Weinshenker; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2019-12-29       Impact factor: 4.982

Review 6.  Galactosemia: Towards Pharmacological Chaperones.

Authors:  Samantha Banford; Thomas J McCorvie; Angel L Pey; David J Timson
Journal:  J Pers Med       Date:  2021-02-07

7.  Neonatal GALT gene replacement offers metabolic and phenotypic correction through early adulthood in a rat model of classic galactosemia.

Authors:  Jennifer M I Daenzer; Shauna A Rasmussen; Sneh Patel; James McKenna; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2022-01-14       Impact factor: 4.750

8.  A pilot study of neonatal GALT gene replacement using AAV9 dramatically lowers galactose metabolites in blood, liver, and brain and minimizes cataracts in GALT-null rat pups.

Authors:  Shauna A Rasmussen; Jennifer M I Daenzer; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2020-09-17       Impact factor: 4.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.